Next, we evaluated the potential antitumor effect of FRBs, studying cell proliferation and apoptosis in patient-derived GSCs and in glioma cells, and compared them to Tubastatin A. For this, cells were cultured with increasing doses for 48 h, and the expression of different markers, Ki67 and phospho-histone 3 (p-H3) for proliferation and cleaved caspase-3 for apoptosis, was analyzed. Here, MKI67 is linked to glioma.